ArticleJournal of translational medicine2025
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Construction of a risk scoring model based on machine learning and validation of the role of the key gene SERPINE1 in the progression of colon cancer.Cancer cell international · 2026Article
- Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundRAS mutations, present in 40-50% of metastatic colorectal cancer (mCRC) cases, drive oncogenic signaling and confer resistance to anti-EGFR therapies. Tumor mutational burden (TMB), a marker of genomic instability, has recently emerged as a predictive biomarker of response to immunotherapy. However, the prognostic interaction between RAS status and TMB in mCRC remains poorly defined. PATIENTS AND
methodsWe analyzed 108 patients with microsatellite-stable metastatic colon cancer (mCC). Tumor samples were profiled using the TruSight Oncology
resultsRAS mutations were associated with reduced OS (46.4 vs. 67.9 months for mutant vs. wild-type; HR 1.76; P = 0.0495). Stratified analysis showed that the adverse effect of RAS mutations was restricted to patients with low TMB (< 10 mutations/Mb). The subgroup with both RAS mutations and low TMB had the poorest OS (28.0 months; HR 2.34; P = 0.0058), whereas patients with either RAS wild-type or high TMB showed comparable survival. GO analysis revealed enrichment of receptor-mediated signaling pathways in RAS-mutant/TMB-low tumors. Phenolyzer highlighted distinct molecular networks, with APC, TP53, and ERBB2 as central hubs in RAS-mutant/TMB-low tumors, and APC, TP53, and BRCA1 in RAS-wild-type/TMB-high tumors.
conclusionsThis study demonstrates a prognostic interaction between RAS mutations and TMB in mCC, identifying the RAS-mutant/TMB-low subgroup as having the poorest outcomes. Integrative bioinformatic analyses suggest distinct biological mechanisms underlying these differences. These findings support the development of tailored therapeutic and monitoring strategies for specific molecular subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.